Advertisement

Designing Future Clinical Trials for Acute Exacerbations of Chronic Bronchitis

  • M. Miravitlles

Abstract

To some extent, chronic bronchitis can be considered an orphan disease. In fact, most (if not all) of the drugs used in the stable phase of the disease have been initially developed for treating asthma. Similarly, most trials aimed at demonstrating the efficacy of antibiotics in acute exacerbations (AECB) have been modelled on pneumonia studies. Research in both asthma and pneumonia has been the inspiration of subsequent studies in chronic bronchitis in many cases. Furthermore, a specific approach to the disease which takes into account its unique characteristics has seldom been used by researchers.

Keywords

Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease Patient Acute Exacerbation Chronic Bronchitis Respir Crit 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA (1987) Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106:196–204PubMedGoogle Scholar
  2. 2.
    Allegra L, Grassi C, Grossi E, Pozzi E, Blasi F, Frigerio D, et al. (1991) Ruolo degli antibiotici nel trattamento delle riacutizzazioni della bronchite cronica: risultati di uno studio italiano multicentrico. Ital J Chest Dis 45:138–148Google Scholar
  3. 3.
    Saint S, Bent S, Vittinghoff E, Grady D (1995) Antibiotics in chronic obstructive pulmonary disease exacerbations: a meta-analysis. JAMA 273:957–960PubMedCrossRefGoogle Scholar
  4. 4.
    Sachs APE, Köter GH, Groenier KH, van der Waaij D, Schiphuis J, Meyboom-de Jong B (1995) Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 50:758–763PubMedCrossRefGoogle Scholar
  5. 5.
    Chodosh S, DeAbate CA, Haverstock D, Aneiro L, Church D and the Bronchitis Study Group (2000) Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Respir Med 94:18–27PubMedCrossRefGoogle Scholar
  6. 6.
    Wilson R, Kubin R, Ballin I, Deppermann KM, Bassaris HP, Leophonte P, et al. (1999) Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 44:501–513PubMedCrossRefGoogle Scholar
  7. 7.
    Grossman R, Mukherjee J, Vaughan D, Eastwood C, Cook R, LaForge J, et al. (1998) A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 113:131–141PubMedCrossRefGoogle Scholar
  8. 8.
    DeAbate CA, Henry D, Bensch G, Jubran A, Chodosh S, Harper L, et al. (1998) Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis. A multicenter, double-blind, randomized, comparative study. Chest 114:120–130PubMedCrossRefGoogle Scholar
  9. 9.
    Miravitlles M, Murio C, Guerrero T, Segu JL (1999) Costs derived from management of acute exacerbations of chronic bronchitis and COPD. Eur Respir J 14 (Suppl 30):115sGoogle Scholar
  10. 10.
    MacFarlane JT, Colville A, Guion A, MacFarlane RM, Rose DH (1993) Prospective study of aetiology and outcome of adult lower respiratory tract infections in the community. Lancet 341:511–514PubMedCrossRefGoogle Scholar
  11. 11.
    Ball P, Harris JM, Lowson D, Tillotson G, Wilson R (1995) Acute infective exacerbations of chronic bronchitis. Q J Med 88:61–68Google Scholar
  12. 12.
    Huchon GJ, Gialdroni-Grassi G, Leophonte P, Manresa F, Schaberg T, Woodhead M (1996) Initial antibiotic therapy for lower respiratory tract infection in the community: a European survey. Eur Respir J 9:1590–1595PubMedCrossRefGoogle Scholar
  13. 13.
    Davey P, Rutherford D, Graham B, Lynch B, Malek M (1994) Repeat consultations after antibiotic prescribing for respiratory infection: a study in one general practice. Br J Gen Pract 44:509–513PubMedGoogle Scholar
  14. 14.
    Murata GH, Gorby MS, Kapsner CO, Chick TW, Halperin AK (1992) A multivariate model for predicting hospital admissions for patients with decompensated chronic obstructive pulmonary disease. Arch Intern Med 152:82–86PubMedCrossRefGoogle Scholar
  15. 15.
    Osman LM, Godden DJ, Friend JAR, Legge JS, Douglas JG (1997) Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 52:67–71PubMedCrossRefGoogle Scholar
  16. 16.
    Antonelli Incalzi R, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, et al. (1997) Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 10:2794–2800Google Scholar
  17. 17.
    Prescott E, Lange P, Vestbo J (1995) Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 8:1333–1338PubMedCrossRefGoogle Scholar
  18. 18.
    Landbo C, Prescott E, Lange P, Vestbo J, Almidal TP. (1999) Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160:1856–1861PubMedGoogle Scholar
  19. 19.
    Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E (1999) Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 159:158–164PubMedGoogle Scholar
  20. 20.
    Connors AF Jr, Dawson NV, Thomas C, Harrel FE Jr, Desbiens N, Fulkerson WJ, et al. (1996) Outcomes following acute exacerbation of severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 154:959–967PubMedGoogle Scholar
  21. 21.
    Miravitlles M, Espinosa C, Fernändez-Laso E, Martos JA, Maldonado JA, Gallego M and Study Group of Bacterial Infection in COPD (1999) Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 116: 40–46.PubMedCrossRefGoogle Scholar
  22. 22.
    Murata GH, Kapsner CO, Lium DJ, Busby HK (1998) Time course of respiratory decompensation in chronic obstructive pulmonary disease: a prospective, doubleblind study of peak flow changes prior to emergency department visit. Respir Med 92:936–941PubMedCrossRefGoogle Scholar
  23. 23.
    Monsó E, Ruiz J, Rosell A, Monterola J, Fiz J, Morera J, Ausina V (1995) Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 152:1316–1320PubMedGoogle Scholar
  24. 24.
    Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Xaubet A (1999) Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 14:1015–1022PubMedCrossRefGoogle Scholar
  25. 25.
    Agustí AGN, Villaverde JM, Togores B, Bosch M (1999) Serial measurements of exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease. Eur Respir J 14:523–528PubMedCrossRefGoogle Scholar
  26. 26.
    Hill AT, Campbell EJ, Bayley DL, Hill SL, Stockley RA (1999) Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha-1-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med 160:1968–1975PubMedGoogle Scholar
  27. 27.
    Dev D, Wallace E, Sankaran R, Cunnife J, Govan JRW, Wathen CG, et al. (1998) Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med 92:664–667PubMedCrossRefGoogle Scholar
  28. 28.
    Davies L, Angus RM, Calverley PMA (1999) Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 354:456–460PubMedCrossRefGoogle Scholar
  29. 29.
    Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA (1998) Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:1418–1422PubMedGoogle Scholar
  30. 30.
    Di Stefano A, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P, et al. (1998) Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 158:1277–1285PubMedGoogle Scholar
  31. 31.
    Stockley RA (1998) Role of bacteria in the pathogenesis and progression of acute and chronic lung infection. Thorax 53:58–62PubMedCrossRefGoogle Scholar
  32. 32.
    Miravitlles M, de Gracia J, Rodrigo MJ, Cruz MJ, Vendrell M, Vidal R, et al. (1999) Specific antibody response against the 23-valent pneumococcal vaccine in patients with alpha-1-antitrypsin deficiency with and without bronchiectasis. Chest 116:946–952PubMedCrossRefGoogle Scholar
  33. 33.
    Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchinson DCS, Ulrik CS, et al. (1999) A randomized clinical trial of alpha-1-antitrypsin augmentation therapy. Am J Respir Crit Care Med 160:1468–1472PubMedGoogle Scholar
  34. 34.
    Davey PG, Malek MM, Parker SE (1992) Pharmacoeconomics of antibacterial treatment. Pharmacoeconomics 1:409–437PubMedCrossRefGoogle Scholar
  35. 35.
    Soler N, Torres A, Ewig S, Gonzalez J, Celis R, El-Ebiary M, et al. (1998) Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 157:1498–1505PubMedGoogle Scholar
  36. 36.
    Murphy TF, Sethi S, Klingman KL, Brueggemann AB, Doern GV (1999) Simultaneous respiratory tract colonization by multiple strains of nontypeable haemophilus influenzae in chronic obstructive pulmonary disease: implications from antibiotic therapy. J Infect Dis 180:404–409PubMedCrossRefGoogle Scholar
  37. 37.
    Miravitlles M, Mayordomo C, Artés M, Sénchez-Agudo L, Nicolau F, Segú JL on behalf of the EOLO Group (1999) Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. Respir Med 93:173–179PubMedCrossRefGoogle Scholar
  38. 38.
    Thompson WH, Nielson CP, Carvalho P, Charan N, Crowley J (1996) Controlled trial of oral prednisone in outpatients with acute COPD exacerbations. Am J Respir Crit Care Med 154:407–412.PubMedGoogle Scholar
  39. 39.
    Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, et al. (1999) Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 340:1941–1947PubMedCrossRefGoogle Scholar
  40. 40.
    Wilson R, Tillotson G, Ball P (1996) Clinical studies in chronic bronchitis: a need for a better definition and classification of severity. J Antimicrob Chemother 37:205–207PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2000

Authors and Affiliations

  • M. Miravitlles
    • 1
  1. 1.Servei de PneumologiaHospital General Vall d’HebronBarcelonaSpain

Personalised recommendations